Mineralys Therapeutics (MLYS) Insider Karydas Sells $75K of Stock

Daphne Karydas sold 3,000 shares of Mineralys Therapeutics, Inc. (MLYS) on June 17, 2026. The sale was executed at an average price of $25.00 per share, making the total value of the transaction $75,000. This move was disclosed in a recent filing with the Securities and Exchange Commission.

The trade was not a spontaneous decision. It followed a Rule 10b5-1 trading plan, which is a tool that lets company insiders schedule stock trades ahead of time. On that same day, Karydas also acquired 3,000 shares at a price of $12.02, effectively exercising options and immediately selling the resulting shares. After these transactions, the insider's direct ownership remained unchanged from the start of the day.

Mineralys Therapeutics Stock Performance

Shares of Mineralys Therapeutics were trading at $25.13 on Thursday. The stock has experienced a fairly wide range over the past year, reaching as high as $47.65 and dipping as low as $22.30. At its current price, the company has a market value of roughly $2.5 billion. The stock is currently trading slightly below its 200-day moving average of $28.95, a common technical level that traders watch to gauge long-term price trends.

Multiple Insiders Active at Mineralys

Karydas wasn't the only person at the company busy with trades in mid-June. On the same day, Chief Medical Officer Rodman David Malcom also exercised options to buy ,4584 shares at $14.36 and sold them at $25.00 under a similar pre-arranged plan. Later in the month, on June 26, 2026, Chief Commercial Officer Eric Warren bought 104,124 shares at $13.24. These combined actions show a high level of activity among the leadership team during the early summer months.

Analysts Set New Price Targets

Several research firms have recently updated their views on the stock. On October 12, 2026, UBS started coverage on Mineralys Therapeutics, giving it a Neutral rating and a price target of $29.00. That same day, H.C. Wainwright & Co. stood by its Buy rating, setting a much higher price target of $56.00. Across the eight analysts who follow the company, the average price target is $48.50, suggesting a generally positive outlook from Wall Street professionals.

About Mineralys Therapeutics

Mineralys Therapeutics is a biotechnology firm based in Radnor, Pennsylvania. The company focuses on developing new treatments for health issues caused by high levels of aldosterone, a hormone that can damage the heart and kidneys. Its main project is a drug called lorundrostat, which is being tested for patients struggling with high blood pressure, chronic kidney disease, and sleep apnea. Because the company is still in the development phase, it does not currently turn a profit and reported a loss of $4.20 per share.

What to Watch at Mineralys Therapeutics, Inc.

Investors will likely look to the company's next earnings report, scheduled for November 10, 2026, for updates on its clinical trials. While insider sales can sometimes catch the eye of the public, they are often planned months in advance for personal financial management. Future SEC filings will show if other executives decide to follow suit or if the recent buying trend by the Chief Commercial Officer continues.